The weekly extended-release formulation uses a subcutaneous injection (a slow-release shot placed under the skin) that lasts seven days. The patient receives one injection per week instead of daily medication.

What did the trial find?

NIDA's announcement described the results as supporting weekly extended-release buprenorphine during pregnancy. The agency did not release specific numerical results in its summary.

Readers should wait for the full peer-reviewed publication to assess:

• Sample size
• Statistical comparisons
• Subgroup effects by trimester
• Long-term infant follow-up

Why does this matter clinically?

Pregnant patients with OUD have historically had fewer medication options than non-pregnant adults. Many compounds carry uncertain fetal risks. Stigma around medication treatment adds another barrier.

If weekly buprenorphine proves equivalent in safety and effectiveness to daily buprenorphine, clinicians gain a new tool. A once-weekly injection could ease adherence challenges. Weekly dosing may also improve consistency of medication coverage.

Extended-release buprenorphine is already FDA-approved for non-pregnant adults. Its use in pregnancy has been off-label until now. Stronger evidence may eventually support a label expansion or revised clinical guidelines.

What limitations does the trial have?

The NIDA announcement is a top-line summary. It signals direction but does not replace a peer-reviewed paper with full methodology.

Key open questions remain:

• How many participants were enrolled
• How long patients were followed
• Whether outcomes differed between groups
• Whether findings apply across pregnancy trimesters

NIDA has historically emphasized replication of single-trial findings before changing clinical practice.

What comes next?

Clinicians who treat pregnant patients with opioid use disorder will be watching for the detailed publication. If the data confirm the announcement, weekly buprenorphine could become a more frequently recommended option.